Drug maker TaiGen Biotechnology Co (太景生技) said yesterday that a drug it developed to treat pneumonia and skin infections was approved on Dec. 20 for the US Food and Drug Administration (FDA) fast track development system, which could result in it receiving a drug permit at an earlier date.
FREQUENT MEETINGS
“Being on the fast track will allow us to meet with officials from the US Food and Drug Administration more frequently, allowing us to provide them with necessary data and meet their requirements within a shorter period of time,” TaiGen vice president Peter Tsao (邵榮凱) said by telephone yesterday. Tsao did not give an estimate for when the drug will be approved.
Tsao said the reason the medication was put on the fast track was because the drug — nemonoxacin — targets an unmet medical need in the US.
Meanwhile, the US government also agreed to grant TaiGen and its partners exclusive rights to sell the drug for 10 years after it goes on sale in the US market, the company said.
PATENT ISSUES
The company already has a patent for nemonoxacin until 2029, and the rights granted by the US government will provide the firm with extra protection as the patent is likely to be challenged by other companies, Tsao said.
CLINICAL TRIALS
Having passed Phase II clinical trials in the US, the TaiGen drug is ready Phase III trials and the company is looking for firms to purchase the drug, Tsao said. The fast track status and exclusive rights will make the drug more attractive for potential partners, he added.
From January through last month, TaiGen registered revenues of NT$63.35 million, up 84.51 percent from NT$34.33 million a year ago, according to the company’s filing to the Taiwan Stock Exchange.
However, the company still posted losses of NT$271.86 million in the January to September period as the result of its high research and development costs, the filing showed. The figure was down 48.39 percent from losses of NT$526.73 million last year.
Taiwan’s foreign exchange reserves fell below the US$600 billion mark at the end of last month, with the central bank reporting a total of US$596.89 billion — a decline of US$8.6 billion from February — ending a three-month streak of increases. The central bank attributed the drop to a combination of factors such as outflows by foreign institutional investors, currency fluctuations and its own market interventions. “The large-scale outflows disrupted the balance of supply and demand in the foreign exchange market, prompting the central bank to intervene repeatedly by selling US dollars to stabilize the local currency,” Department of Foreign
ENERGY ISSUES: The TSIA urged the government to increase natural gas and helium reserves to reduce the impact of the Middle East war on semiconductor supply stability Chip testing and packaging service provider ASE Technology Holding Co (日月光投控) yesterday said it planned to invest more than NT$100 billion (US$3.15 billion) in building a new advanced chip testing facility in Kaohsiung to keep up with customer demand driven by the artificial intelligence (AI) boom. That would be included in the company’s capital expenditure budget next year, ASE said. There is also room to raise this year’s capital spending budget from a record-high US$7 billion estimated three months ago, it added. ASE would have six factories under construction this year, another record-breaking number, ASE chief operating officer Tien Wu
Intel Corp is joining Elon Musk’s long-shot effort to develop semiconductors for Tesla Inc, Space Exploration Technologies Corp and xAI, marking a surprising twist in the chipmaker’s comeback bid. Intel would help the Terafab project “refactor” the technology in a chip factory, the company said on Tuesday in a post on X, Musk’s social media platform. That is a stage in the development process that typically helps make chips more powerful or reliable. The chipmaker’s shares jumped 4.2 percent to US$52.91 in New York trading on Tuesday. The Terafab project is a grand plan by Musk to eventually manufacture his own chips for
For weeks now, the global tech industry has been waiting for a major artificial intelligence (AI) launch from DeepSeek (深度求索), seen as a benchmark for China’s progress in the fast-moving field. More than a year has passed since the start-up put Chinese AI on the map in early last year with a low-cost chatbot that performed at a similar level to US rivals. However, despite reports and rumors about its imminent release, DeepSeek’s next-generation “V4” model is nowhere in sight. Speculation is also swirling over the geopolitical implications of which computer chips were chosen to train and power the new
RSS